71RO Sustained remission and long-term survival outcomes with dostarlimab plus chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

Dostarlimab + carboplatin-paclitaxel (DOST+CP) demonstrated statistically significant PFS and clinically meaningful OS benefits in patients (pts) with dMMR/MSI-H primary advanced or recurrent endometrial cancer (pA/R EC) in Part 1 of the phase III RUBY trial (NCT03981796). Here, we report updated efficacy with 4 y of follow-up in pts with dMMR/MSI-H pA/R EC and further summarized characteristics of pts with long-term disease control.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2026-07-01
DOI
https://doi.org/10.1016/j.esmoop.2026.108097
Primary Topic
Endometrial and Cervical Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

71RO Sustained remission and long-term survival outcomes with dostarlimab plus chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

R W Holloway, L. Gilbert, M. Edelson, S.E. Gill et al.
ESMO Open
Endometrial and Cervical Cancer Treatments
article

71RO Sustained remission and long-term survival outcomes with dostarlimab plus chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

R W Holloway, L. Gilbert, M. Edelson, S.E. Gill, S. Kommoss, T.J. Herzog, M.A. Powell, V.S. Sukhin, A. Koliadi, J. Diaz, A.M. Thijs, T. Myers, G. Ronzino, B.J. Monk, E.M. Miller, L. Austin, I. Podzielinski, T. Jakobi Nøttrup, C. Mathews, B. Patel
article en

Abstract

Dostarlimab + carboplatin-paclitaxel (DOST+CP) demonstrated statistically significant PFS and clinically meaningful OS benefits in patients (pts) with dMMR/MSI-H primary advanced or recurrent endometrial cancer (pA/R EC) in Part 1 of the phase III RUBY trial (NCT03981796). Here, we report updated efficacy with 4 y of follow-up in pts with dMMR/MSI-H pA/R EC and further summarized characteristics of pts with long-term disease control.

ESMO OpenVol. 11
Gynecologic Oncology Group (US), Baptist Hospital of Miami (US), Allegheny Health Network (US), Baystate Medical Center (US), Radboud University Nijmegen (NL), Washington University in St. Louis (US), Catharina Ziekenhuis (NL), Cancer Research UK (GB), McGill University Health Centre (CA), Florida Hospital Cancer Institute (US), Nordic Society of Gynecologic Oncology (DK), München Klinik Schwabing (DE), Baptist Health South Florida (US), GlaxoSmithKline (United States) (US), Florida Cancer Specialists & Research Institute (US), St. Joseph’s Candler Hospital (US), Women & Infants Hospital of Rhode Island (US), National Academy of Medical Sciences of Ukraine (UA), Parkview Health (US), Ospedale Vito Fazzi (IT), Kharkiv National Medical University (UA), University of Cincinnati Medical Center (US)
Good health and well-being
Openalex Percentile: Top 6%
Endometrial and Cervical Cancer Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.